Inside every human cell, thousands of proteins are constantly being made, used, and disposed of, their abundance shifting as the cell's needs change. A team of molecular regulators keeps this balance in check, and one important class of players is the Argonaute (Ago) proteins. Now, researchers at Cold Spring Harbor Laboratory (CSHL) have captured the first full pictures of a microRNA guide carried by the Argonaute2 protein (Ago2) and bound to its target RNA, offering new insight into how this delicate balancing act is maintained.
According to CSHL, Professor Leemor Joshua-Tor and Research Investigator Ankur Garg used cryo-electron microscopy (cryo-EM) to image the complex. Ago2 functions as a component of a molecular mechanism that reduces the rate at which specific proteins are created, either by altering or isolating the RNA molecules that carry the blueprints for their assembly. This mechanism relies on small RNA fragments known as microRNA (miRNA), which attach to a target RNA destined for removal. This phenomenon, referred to as RNA interference, plays a vital role in human well-being—when the equilibrium of proteins within our cells is disrupted, it can increase susceptibility to cancer, neurodegenerative disorders, viral infections, and other diseases.
Joshua-Tor initially revealed the structure of Ago2 in 2004, and together with the late former CSHL Professor Greg Hannon, showed that Ago2 is at the heart of RNA interference. Her team has since revealed many features of how Ago2 works by capturing detailed images of the protein. Their latest work shows, the first-ever complete view of a miRNA guide held by Ago2 and attached to its target RNA. This connection is short-lived. Once Ago2 has completed silencing a target, it releases it and proceeds to locate another target to silence. The team's latest cryo-EM images, captured by Garg, show how that happens. The images show not just Ago2 and the two RNAs, but also a partner protein called CK1α. CK1α helps push the target RNA away by attaching negatively charged chemical groups to Ago2.
That chemical shove wouldn't do much if the target RNA were tightly entwined with Ago2's miRNA. But the new pictures show that's not the case. "Right in the middle of this interaction between the miRNA and the target RNA, where we really couldn't see anything before, the protein is holding the two strands in an untwisted conformation," Joshua-Tor explained. "It's kind of prying it open."
But that isn't the whole story. The miRNA's association with its target also causes Argonaute to open up so that CK1α can do its job. Joshua-Tor noted that Ago-mediated gene regulation is a major target of drug development. Several already-approved treatments for human disease work by modulating RNA interference, and many other, more experimental therapies are in the pipeline. "So," she added, "the more we know about how Argonaute works, the better."
The findings were published in Nature Communications on October 24, 2026, with Garg as lead author. The research was supported by the Howard Hughes Medical Institute, the National Cancer Institute, the CSHL School of Biological Sciences, and the National Science Foundation.
For students studying molecular biology, biochemistry, or medicine, this work provides a clearer structural understanding of a fundamental cellular process that underpins a growing class of therapeutics. RNA interference is already the basis for several FDA-approved drugs, and a deeper grasp of how Ago2 releases its targets could inform the design of more effective treatments for diseases ranging from cancer to viral infections.